Servier FAST Discovery Award

As a company committed to therapeutic progress to serve patient needs, Servier takes an open and collaborative approach to R&D at every stage of the drug development life cycle, including early-stage discovery – where we are proud to support the next generation of innovation.

Our Servier Discovery Award to the CLS FAST program recognizes the aspiring life-science companies and entrepreneurs who are driving scientific innovation in areas of high unmet need, including hard-to-treat diseases in oncology, neuroscience and immuno-inflammation, as well as those pursuing research in translational medicine, drug development technologies and drug delivery platforms.

About the Application Process

Servier is interested in applications for the Servier Discovery Award to interested startups developing innovative approaches in the following discovery and early clinical areas of interest:

  • Innovative therapeutic approaches in:
    • Oncology: Cancer cell targeting (e.g., synthetic lethality, precision oncology) and immuno-oncology (e.g., tumor micro-environment, T-cell targeting)
    • Neuroscience: Rare neurological disorders (e.g., Familial Amyotrophic Lateral Sclerosis, genetically driven pediatric epilepsies) and sub-populations of neurodegenerative diseases
    • Immuno-inflammation: Autoantibody-driven autoimmune diseases and related conditions with similar pathophysiological mechanisms
  • Novel modality development strategies for small molecules, biologics (including bi-specifics, ADCs) and oligonucleotides (including ASOs), as well as targeted delivery strategies (e.g., tumor-specific, CNS delivery mechanisms)
  • AI/ML data-driven platforms for drug design (including oligonucleotides and antibodies) and to support translational activities (target and biomarker identification)

How To Apply

Your non-confidential application should highlight your innovative approach to advancing therapies for patients with high unmet needs. All submissions are reviewed by Servier to select one awardee. Winner of the Servier Discovery Award will get a fast-tracked spot in the Fall 2023 FAST accelerator program that includes an opportunity to pitch to a panel of investors on Dec 12, 2023 in San Francisco. Learn more details about the FAST program here.


  • July 1, 2023: Application due Date
  • Aug 31, 2023: Servier Discovery Award announced.
  • Sept 22, 2023: Program Kickoff meeting (virtual)
  • Dec 12, 2023: Innovation Showcase pitch event (in person in San Francisco)


The winner of the “Servier Discovery Award” shall fast tracked into the Fall 2023 cohort of CLS FAST accelerator program. A dedicated advisor from Servier will be attending (virtually) the advisory meetings of the Awardee. Recipient shall not receive consideration in the form of cash. Recipients seeking access to, and discussions with, Servier employees in the form of guidance or feedback may be required to execute appropriate confidentiality agreements, at Servier’s discretion.

Any questions or comments can be directed to Shikha Sharma at [email protected].

Servier as a Partner-of-Choice

  • Independent, ensuring continuity and long-term perspective in partnerships
  • Committed to serving patient needs by working with patients at all stages of the drug development life cycle
  • Global geographical footprint, with a presence in both established and emerging markets
  • Science driven and substantial R&D investment designed to build a high-quality and sustainable portfolio
  • Strong capabilities from research to commercialization
  • Over 70 active global partnerships across pharma, biotech and academia

About Servier

Servier Pharmaceuticals is a privately held pharmaceutical company focused on Oncology. Everything we do is to bring the promise of tomorrow to the patients we serve. Learn More 

Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities.

With more than 60 years of experience in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.

As a leader in oncology, Servier is committed to finding solutions that will address today’s challenges. The company is pioneering the science behind IDH mutations, bringing new therapeutic options to patients, and investing in people, infrastructure and innovation at a time when most industry peers are scaling back. In oncology, Servier is also targeting apoptosis in immuno-oncology and cell metabolism.

Servier has experienced exponential growth since opening its doors in the United States in 2018, quadrupling its oncology portfolio from one to five assets in less than four years. The company’s oncology portfolio includes innovative medicines designed to bring more life-saving treatments to a greater number of patients, with 25 oncology assets at varying stages of clinical development, and 20 research projects across the entire spectrum of disease and in a variety of tumor types.

In the past year, Servier has received two ground breaking FDA approvals, including the company’s entrance into solid tumors with cholangiocarcinoma. Additionally, Servier is expanding its pipeline with seven potential additions, including two new products in solid tumors, expecting to reach $1 billion in organic growth and receive three additional FDA approvals in the next five years.

Servier’s ongoing success in the U.S., both clinically and commercially, has allowed the company to expand its footprint in the Boston Seaport with the launch of a new office and $10 million-dollar state-of-the-art lab space.

Servier believes co-creation is fundamental to driving innovation and is actively building alliances, acquisitions, licensing deals and partnerships that bring solutions and accelerate access to therapies to patients.

More information:

More from Servier


Our partnerships are a core part of our business. We are seeking partners who share our values and commitment to improving the lives of patients, caregivers and families we serve. Learn More 

Research & Development

We invest in innovative research and development through our own development or partnerships to best address the unmet needs of patients. Learn More